← Leaderboards
Rafet Basar
University Of Tx Md Anderson Can Ctr
$1,227,277
Attributed
$3,681,832
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2023–25$5M$3.8M$2.5M$1.3M$0
'23
'24
'25
Funding mix
By agency
NIH$3,681,832 · 3
By mechanism
R01$3,681,832 · 3
Top collaborators
- Katy Rezvani6 shared
- May Daher4 shared
- Hind Rafei2 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Katy Rezvani$10,195,970
- Indreshpal Kaur$1,947,447
- Dapeng Zhou$1,875,527
- Juan Fueyo$8,546,462
- Ruitao Lin$859,215
Others in their field
Other Rising Stars on “Interleukin-15”
- Andras A. Heczey · Baylor College Of Medicine$2,725,684
- Hua Wang · University Of Illinois At Urbana-Champaign$2,229,562
- Ming Yang · Mucommune, Llc$2,178,184
- Fernanda Novais · Ohio State University$1,680,973
- Colleen Doyle Cooper · Celdara Medical, Llc$1,228,902
- Kevin C Barry · Fred Hutchinson Cancer Center$1,093,243
Research focus
Interleukin-15Manufacturing ProcessFirst-In-HumanInnovationIn VivoEngineered Nk CellCryopreservationClinicGraft Vs Host DiseaseImproved OutcomeDoseEventB Lymphoid MalignancyAllogenicBiobankCellular TransductionAdoptive TransferCellsCasp9 GeneCostChimeric Antigen Receptor T CellsCell TherapyAutologousMetabolic Fitness
Grant awards (6)
Advancing next-generation CAR-NK therapies targeting CD5 positive T cell malignancies to the clinic$1,847,485
R01 · FY2025 · CA
Next Generation Engineered NK Cells for Lymphoma Patients after CD19 CAR-T Cell Failure.$370,575
R01 · FY2025 · CA
TROP2-Directed CAR-NK Cells for the Immunotherapy of Pancreatic Cancer$370,575
R01 · FY2025 · CA · contact PI
TROP2-Directed CAR-NK Cells for the Immunotherapy of Pancreatic Cancer$370,575
R01 · FY2024 · CA · contact PI
Next Generation Engineered NK Cells for Lymphoma Patients after CD19 CAR-T Cell Failure.$352,047
R01 · FY2024 · CA
Next Generation Engineered NK Cells for Lymphoma Patients after CD19 CAR-T Cell Failure.$370,575
R01 · FY2023 · CA